Hims & Hers Health enters the final stretch before its June 11 results with short sellers dug in, a lead director buying the dip, and analysts still unable to agree on whether the worst is priced in.
The short positioning tells a story of a crowded trade that has found its floor. Short interest is 29.2% of the free float — fractionally higher on the week — after dropping sharply from the late-April peak above 39%. The covering wave has fully stalled. More significantly, availability has been at zero percent for over a week, meaning every share in the lending pool is already out on loan. That is the tightest the borrow market has been since mid-April. Yet cost to borrow remains cheap at just 1.03% APR, down 13% on the week and 23% over the past month — a signal that while the trade is crowded, lenders are not yet charging a premium to stay in. The ORTEX short score is 68.4, ranking in the bottom 6th percentile of the universe, and availability ranks in the bottom 5th percentile. This is a structurally loaded short book that is neither covering nor being squeezed.
Options traders are reading the same data differently. The put/call ratio has drifted down to 0.62, below its 20-day average of 0.66 and close to its 52-week low of 0.58. That tilt toward calls is notable against a backdrop of near-zero availability and 29% short interest — options buyers are leaning bullish even as the borrow market stays fully tapped. The z-score on the PCR is slightly negative at -0.94, confirming the call-side skew is mild rather than extreme, but the direction of travel is clear: options positioning has grown progressively more bullish over the past three weeks as the stock recovered 6% from its recent lows.
The single most eye-catching data point this week is a $1.17 million open-market purchase by David Wells, the Lead Independent Director, on May 26 at $24.24 per share. That is a material conviction buy from a board insider at a price that is 22% below where the CFO was selling in mid-April. The CFO, Oluyemi Okupe, has sold on multiple occasions — roughly $2.3 million across April and May — though those sales appear linked to a pre-arranged programme. Wells's purchase has no such pattern, and it stands out against a 90-day insider net that is modestly positive overall at around $37 million net bought. Institutional positioning shows BlackRock adding incrementally at 11.4% of shares, while Renaissance Technologies cut its position by 2.7 million shares in the latest filing.
The Street is cautious but not uniformly negative. B of A Securities has trimmed its target three times in the past two weeks — from $32 down to $25 — while holding a Neutral rating throughout, a persistent ratchet lower that reflects post-earnings disappointment rather than a fresh thesis shift. JPMorgan, which initiated at Overweight with a $35 target on April 24, trimmed to $33 after the Q1 miss. Needham is the outlier, raising its Buy target from $30 to $35 on May 12. Truist moved the other way, lifting its Hold target from $18 to $23. The consensus mean sits at $26.61, roughly 11.5% above the current $23.85 price — a slim premium that reflects a broadly neutral Street rather than strong conviction in either direction. The bull case centres on the Novo Nordisk partnership and GLP-1 market expansion; the bear case is straightforward: Q1 revenue and EBITDA missed, margins are under pressure, and the shift from compounded to branded GLP-1 products carries higher costs and insurance complexity.
The earnings history adds a layer of caution. The last print on May 11 produced an 11.5% one-day drop and a 21% five-day decline — the sharpest reaction in the recent record. The prior quarter saw a modest 3.9% fall followed by a 6% recovery over five days. The June 11 date is therefore squarely on the radar for anyone holding a short or a long into month-end. With availability at zero, short interest stable at 29%, and a board director buying at current levels, the setup heading into that print is less about directional consensus and more about whether the lending market stays locked or starts to ease.
See the live data behind this article on ORTEX.
Open HIMS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
